Orexigen Therapeutics (OREX) Surges on BofA Upgrade
Tweet
Share
E-mail
Get Alerts OREX Hot Sheet
Price: $0.22 --0%
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Orexigen Therapeutics, Inc. (Nasdaq: OREX) is surging in pre-open action Monday after BofA/Merrill Lynch upgraded the stock to Buy with an aggressive $7 price target, which suggests nearly 100% upside from Friday's close.
The firm said OREX is well positioned if the FDA advisory meeting on 3/28-3/29 favors pre-approval cardiovascular outcomes studies for obesity drugs.
The firm said OREX is well positioned if the FDA advisory meeting on 3/28-3/29 favors pre-approval cardiovascular outcomes studies for obesity drugs.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Mobility Global (MBGL) at Neutral
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- Ensign Group expands credit facility to $800M, extends to 2031
Create E-mail Alert Related Categories
Hot Upgrades, Momentum Movers, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
